Comparative Pharmacology
Head-to-head clinical analysis: ORA TESTRYL versus TESTOSTERONE CYPIONATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ORA TESTRYL versus TESTOSTERONE CYPIONATE.
ORA-TESTRYL vs TESTOSTERONE CYPIONATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Testosterone replacement therapy; binds to androgen receptors, promoting protein synthesis, muscle growth, and secondary sexual characteristic development.
Testosterone cypionate is a synthetic androgen that binds to and activates androgen receptors, leading to increased protein synthesis, muscle growth, and secondary sexual characteristic development. It also suppresses gonadotropin release via negative feedback.
Intramuscular injection: 50-100 mg every 2-4 weeks.
Intramuscular injection of 50-400 mg every 2-4 weeks, typically 200 mg every 2 weeks or 400 mg every 4 weeks.
None Documented
None Documented
Terminal half-life 2.5-3.5 hours; clinical context: requires multiple daily dosing to maintain steady-state levels
Approximately 8 days (terminal elimination half-life of testosterone cypionate after intramuscular injection; due to slow release from oil depot, effective half-life in muscle is ~8 days with a longer terminal phase up to 3 weeks)
Renal (90% as glucuronide and sulfate conjugates, 10% unchanged); Biliary/fecal (10%)
Renal (90% as glucuronide and sulfate conjugates), fecal (10%)
Category C
Category D/X
Androgen
Androgen